Intravitreal bevacizumab

Ophthalmology. 2007 Feb;114(2):400; author reply 400-1. doi: 10.1016/j.ophtha.2006.10.002.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage*
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Choroidal Neovascularization / diagnosis
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / etiology
  • Choroidal Neovascularization / physiopathology
  • Drug Compounding
  • Humans
  • Injections
  • Macular Degeneration / complications
  • Macular Degeneration / diagnosis
  • Macular Degeneration / drug therapy*
  • Macular Degeneration / physiopathology
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A / immunology
  • Visual Acuity / physiology
  • Vitreous Body

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab